NASDAQ:QLGN Qualigen Therapeutics (QLGN) Stock Price, News & Analysis $4.01 +0.48 (+13.63%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Qualigen Therapeutics Stock (NASDAQ:QLGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Qualigen Therapeutics alerts:Sign Up Key Stats Today's Range$3.94▼$5.9750-Day Range$1.67▼$6.0152-Week Range$1.61▼$10.45Volume47.36 million shsAverage Volume1.06 million shsMarket Capitalization$6.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology. Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories. These products support the detection and quantification of biomarkers ranging from infectious disease antigens to tumor-associated proteins. Qualigen’s diagnostic portfolio is sold to reference laboratories, hospital systems and point-of-care facilities across North America, Europe and select markets in Asia. Qualigen BioTherapeutics is focused on developing a pipeline of antibody-based and cell-based immunotherapies targeting both hematologic and solid tumors. Its preclinical programs include monoclonal antibodies directed against validated cancer antigens as well as engineered cell therapies designed to enhance tumor recognition and cytotoxicity. The company applies proprietary protein conjugation and high-throughput screening platforms to advance candidates from lead identification through IND-enabling studies.AI Generated. May Contain Errors. Read More Receive QLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QLGN Stock News HeadlinesQualigen Therapeutics partners with BitGo to execute C10 treasury allocation1 hour ago | msn.comQualigen Therapeutics stock surges after BitGo partnership for crypto treasury1 hour ago | za.investing.com$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.October 24 at 2:00 AM | Weiss Ratings (Ad)Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto TreasuryOctober 24 at 3:12 AM | benzinga.comQualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury AllocationOctober 23 at 4:05 PM | globenewswire.comQualigen Therapeutics, Inc.: Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment ...October 14, 2025 | finanznachrichten.deQualigen Therapeutics, Inc. Launches C10 Cryptocurrency Asset Treasury Purchases Amid Crypto Market VolatilityOctober 12, 2025 | quiverquant.comQQualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?October 12, 2025 | globenewswire.comSee More Headlines QLGN Stock Analysis - Frequently Asked Questions How have QLGN shares performed this year? Qualigen Therapeutics' stock was trading at $4.21 at the beginning of the year. Since then, QLGN shares have increased by 13.4% and is now trading at $4.7740. How were Qualigen Therapeutics' earnings last quarter? Qualigen Therapeutics, Inc. (NASDAQ:QLGN) released its quarterly earnings data on Thursday, August, 14th. The company reported ($1.00) earnings per share for the quarter. When did Qualigen Therapeutics' stock split? Qualigen Therapeutics shares reverse split on the morning of Tuesday, November 5th 2024.The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Qualigen Therapeutics? Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Qualigen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Bank of America (BAC), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT). Company Calendar Last Earnings8/14/2025Today10/24/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QLGN CIK1460702 Webwww.qualigeninc.com Phone(760) 918-9165FaxN/AEmployees50Year Founded1996Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.26 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-202.16% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual Sales$4.98 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.86Miscellaneous Outstanding Shares1,700,000Free Float1,664,000Market Cap$6.00 million OptionableNot Optionable Beta0.32 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:QLGN) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
